What endocrine and monogenic disorders cause hypertension in infants that respond dramatically to ACE inhibitors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Endocrine and Monogenic Causes of Hypertension in Infants Responding to ACE Inhibitors

The monogenic and endocrine causes of infant hypertension that respond dramatically to ACE inhibitors are primarily those involving renin-angiotensin system activation, but importantly, ACE inhibitors are NOT the first-line treatment for most monogenic forms of hypertension in infants—these conditions typically require specific targeted therapies based on their underlying mechanism.

Key Distinction: Renin Status Determines Treatment Response

The critical factor is whether the hypertension involves high renin activity versus low renin activity:

Conditions That May Respond to ACE Inhibitors (High Renin States):

  • Renovascular hypertension (though not strictly endocrine/monogenic)
  • Renin-secreting tumors (rare)

Monogenic Conditions That Do NOT Respond to ACE Inhibitors (Low Renin States):

These are the most common monogenic causes in infants and require alternative therapies 1:

1. Familial Hyperaldosteronism Type I (FH-I/Glucocorticoid-Remediable Aldosteronism)

  • Treatment: Glucocorticoids (dexamethasone), NOT ACE inhibitors
  • Presents with early severe hypertension, often before age 20
  • Due to CYP11B2/CYP11B1 chimeric gene fusion 2
  • Responds dramatically to low-dose glucocorticoids

2. Familial Hyperaldosteronism Type III (FH-III)

  • Treatment: Bilateral adrenalectomy or mineralocorticoid receptor antagonists
  • KCNJ5 gene mutations
  • Severe early childhood hypertension with profound hypokalemia 3
  • ACE inhibitors are ineffective

3. Familial Hyperaldosteronism Type IV (FH-IV)

  • Treatment: Mineralocorticoid receptor antagonists
  • CACNA1H mutations
  • Hypertension and PA before age 10 2, 3

4. Liddle Syndrome

  • Treatment: Amiloride or triamterene (ENaC inhibitors), NOT ACE inhibitors
  • SCNN1G mutations causing constitutive ENaC activation 1
  • Suppressed renin and aldosterone

5. Apparent Mineralocorticoid Excess (AME)

  • Treatment: Amiloride, spironolactone, or eplerenone
  • HSD11B2 mutations (loss of 11β-hydroxysteroid dehydrogenase type 2) 1
  • Cortisol acts as mineralocorticoid
  • ACE inhibitors ineffective

6. Pseudohypoaldosteronism Type II (Gordon Syndrome)

  • Treatment: Thiazide diuretics
  • Increased distal tubule sodium reabsorption 1
  • Low renin, hyperkalemia

7. Congenital Adrenal Hyperplasia (11β- and 17α-hydroxylase deficiencies)

  • Treatment: Glucocorticoid replacement
  • CYP11B1 or CYP17A1 mutations 4, 5
  • Mineralocorticoid excess with suppressed renin

Critical Clinical Pitfall

The most important caveat: All monogenic forms of hypertension manifest with suppressed plasma renin activity (PRA) and increased distal tubular sodium absorption 1. This low-renin state means ACE inhibitors will be ineffective because the renin-angiotensin system is already suppressed.

Diagnostic Algorithm for Infants with Hypertension

  1. Measure plasma renin activity (PRA) and aldosterone

    • Low PRA → suspect monogenic hypertension
    • High PRA → consider renovascular causes (may respond to ACE inhibitors)

  2. Check serum potassium and acid-base status

    • Hypokalemia with metabolic alkalosis → primary aldosteronism spectrum
    • Hyperkalemia with metabolic acidosis → Gordon syndrome

  3. Genetic testing when indicated 1:

    • FH-I screening if family history of early stroke or severe early hypertension
    • KCNJ5 for severe resistant hypertension with profound hypokalemia in infancy
    • CACNA1H/CACNA1D if neurologic symptoms present

Treatment Approach Based on Mechanism

For mineralocorticoid excess states (most common):

  • First-line: Mineralocorticoid receptor antagonists (spironolactone or eplerenone) 6
  • Alternative: ENaC inhibitors (amiloride) for Liddle syndrome or AME 6
  • Specific: Glucocorticoids for FH-I 2
  • Specific: Thiazides for Gordon syndrome 1

ACE inhibitors should be reserved for:

  • Primary hypertension in children (when indicated) 1
  • Hypertension with CKD and proteinuria 1
  • Renovascular hypertension with high renin states

Bottom Line

ACE inhibitors are NOT the dramatic responders in monogenic/endocrine infant hypertension. The dramatic responses occur with mechanism-specific therapies: glucocorticoids for FH-I, amiloride for Liddle syndrome/AME, and mineralocorticoid receptor antagonists for other aldosterone-excess states 1, 2, 1, 6. The key is identifying the low-renin state and pursuing genetic diagnosis to guide targeted therapy.

References

5
Research

Adrenal causes of endocrine hypertension in childhood or adolescence.

Journal of endocrinological investigation, 2025

6
Guideline

primary aldosteronism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2025

Related Questions

In a 71-year-old woman with hypertension and type 2 diabetes who presents with angina and ischemic ST‑segment depression in leads V3‑V5, normal troponin, and symptom resolution after nitroglycerin, and who has received aspirin and a beta‑blocker, what is the next best step in management?
Is it safe to combine benazepril (ACE inhibitor) with metoprolol (beta‑blocker) for hypertension or heart failure, and what are the recommended dosing and monitoring guidelines?
Which β‑blocker is indicated for a patient with hypertensive heart disease or coronary artery disease (CAD) who has subclinical or overt heart failure with preserved ejection fraction (HFpEF) and myocardial ischemia or a prior myocardial infarction?
What are the indications, dosing regimens, contraindications, and monitoring recommendations for beta‑blockers in hypertension, angina, heart failure, and arrhythmias?
In a 55-year-old woman with hypertension resistant to an ACE inhibitor, beta‑blocker, and calcium‑channel blocker, who has borderline hypokalemia, normal sodium, elevated creatinine, left‑ventricular hypertrophy on ECG, no abdominal bruit, and normal fundoscopic findings, what is the most likely cause of her secondary hypertension?
What is the recommended management for a child‑bearing‑age woman with two confirmed positive lupus anticoagulant tests spaced four months apart, documented in both obstetric and non‑obstetric settings?
Can azithromycin (Zithromax) be prescribed for a patient with an upper respiratory infection who is taking tramadol 50 mg three times daily?
At what dose levels and after how many treatment cycles do antimetabolite agents (e.g., methotrexate, 5‑fluorouracil, cytarabine, gemcitabine, pemetrexed) typically cause pancytopenia?
What are the typical symptoms of a concussion?
What is the recommended management for a urinoma?
In a patient post‑cholecystectomy presenting with three weeks of nausea, vomiting, and abdominal bloating, what is the differential diagnosis and recommended work‑up?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.